Recent News

• 05.06.2026 - Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
• 04.21.2026 - Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
• 04.20.2026 - Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
• 04.16.2026 - Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
• 04.15.2026 - Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
• 04.15.2026 - Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
• 04.13.2026 - Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
• 04.13.2026 - Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Recent Filings

• 04.30.2026 - ARS Annual Report to Security Holders
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.23.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.21.2026 - 144 Report of proposed sale of securities
• 04.20.2026 - PRE 14A Other preliminary proxy statements
• 04.15.2026 - EX-99.1 EX-99.1
• 04.15.2026 - 8-K Current report
• 04.15.2026 - 424B5 Prospectus [Rule 424(b)(5)]